“Kardium’s groundbreaking PULSAR pivotal trial showcases the Globe Pulsed Field System’s superior performance in treating paroxysmal atrial fibrillation, with 95% durable pulmonary vein isolation via single applications, zero device-related primary safety events, and 78% of patients arrhythmia-free at 12 months, setting new benchmarks in procedural safety, efficiency, and patient outcomes.”
The PULSAR pivotal trial stands as a cornerstone in the evolution of treatments for paroxysmal atrial fibrillation (PAF), a condition affecting millions across the U.S. where irregular heart rhythms disrupt daily life and elevate risks of stroke and heart failure. Sponsored by Kardium Inc., this multicenter investigational device exemption (IDE) study, registered under NCT05462145, involved 183 patients with symptomatic, drug-refractory PAF. Procedures were conducted at 12 leading electrophysiology centers in North America and Europe, focusing on the Globe Pulsed Field System’s ability to deliver pulsed field ablation (PFA) for pulmonary vein isolation (PVI), a critical step in restoring normal heart rhythm.
The trial’s design emphasized real-world applicability, enrolling patients aged 18 to 80 with documented PAF episodes resistant to at least one antiarrhythmic drug. Exclusion criteria included prior ablations, persistent AFib lasting over seven days, or severe comorbidities like advanced heart failure. Participants underwent PVI using the Globe System, followed by rigorous monitoring via electrocardiograms, Holter devices, and transtelephonic transmissions over 12 months to assess arrhythmia recurrence.
Key Efficacy Outcomes
The Globe System excelled in achieving durable PVI, a hallmark of effective AFib ablation. In the trial, 95% of pulmonary veins remained isolated three months post-procedure, with only one pulsed field application needed per vein in most cases. This single-shot capability minimizes procedural variability and enhances predictability for electrophysiologists.
At the 12-month mark, 78% of patients were free from atrial arrhythmias, defined as no episodes of AFib, atrial flutter, or tachycardia lasting 30 seconds or more. This outcome surpasses many traditional radiofrequency or cryoablation methods, where recurrence rates often hover around 30-40%. Subgroup analyses revealed even stronger results: among patients receiving optimal PFA dosing, freedom from arrhythmia climbed to 84%, highlighting the system’s dose-response precision.
| Metric | Result | Notes |
|---|---|---|
| Acute PVI Success | 100% | Achieved in all treated veins across 183 patients |
| Durable PVI at 3 Months | 95% | Confirmed via remapping in a subset of participants |
| Freedom from Arrhythmia at 12 Months | 78% | Primary efficacy endpoint; 84% in optimized dosing cohort |
| Repeat Ablation Rate | 12% | Low need for re-intervention compared to industry averages |
These figures underscore the Globe System’s role in reducing AFib burden, with patients reporting significant improvements in quality of life metrics, including reduced symptoms like palpitations and fatigue.
Safety Profile
Safety emerged as a standout feature, with a 0% rate of device-related primary safety events. This composite endpoint included severe complications such as cardiac tamponade, stroke, phrenic nerve injury, or atrio-esophageal fistula—issues that plague older ablation technologies. Overall adverse events were minimal: transient issues like groin hematomas occurred in under 5% of cases, resolving without long-term impact.
No instances of pulmonary vein stenosis or esophageal thermal injury were reported, thanks to PFA’s non-thermal mechanism, which selectively targets cardiac cells while sparing surrounding tissues. This tissue-specificity represents a paradigm shift from thermal ablations, potentially broadening eligibility for patients with anatomical complexities or comorbidities.
Procedural Efficiency
The Globe System integrates high-definition mapping, stimulation, and ablation into a single catheter with 122 electrodes, streamlining workflows. Average procedure time was 82 minutes, including mapping and confirmation of isolation—far shorter than multi-catheter approaches that can exceed two hours. Fluoroscopy exposure averaged 12 minutes, reducing radiation risks for both patients and operators.
Electrophysiologists noted the spherical array’s adaptability to varied pulmonary vein anatomies, enabling precise energy delivery without repositioning. This efficiency could translate to higher throughput in busy U.S. cath labs, addressing backlogs in AFib procedures amid rising demand.
Expert Insights
Leading voices in cardiology have hailed the results as transformative. The system’s ability to combine mapping and ablation in one tool simplifies complex cases, allowing for personalized strategies beyond standard PVI, such as targeting rotors or scar tissue. One investigator emphasized its potential in hybrid procedures, where PFA complements surgical interventions for advanced AFib.
From a clinical standpoint, the data supports earlier intervention in PAF progression, potentially averting escalation to persistent forms that require more invasive management.
Market Implications for MedTech Investors
In the burgeoning atrial fibrillation treatment sector, valued at approximately $30 billion globally in 2025 and projected to exceed $32 billion this year with a compound annual growth rate of over 10%, Kardium’s advancements position it as a formidable player. The private Vancouver-based firm, founded in 2007, has secured substantial backing, including a $250 million financing round in mid-2025, bringing total funding to around $575 million from investors like Janus Henderson and Piper Sandler.
This capital infusion supports commercialization following FDA pre-market approval in late 2025, enabling U.S. market entry. Analysts anticipate rapid adoption in high-volume centers, driven by reimbursement codes for PFA that favor efficient, low-complication devices. Potential revenue streams include system sales, disposables, and software upgrades for mapping analytics.
Valuation estimates place Kardium in the $1-2 billion range, reflecting its differentiated technology amid a wave of medtech consolidations. Acquisitions in the PFA space, such as those by larger incumbents, could yield premiums for innovative entrants like Kardium.
Competitive Landscape
The PFA arena is heating up, with Kardium’s Globe System differentiating through its all-in-one design. Rivals include Medtronic’s PulseSelect, a single-shot ablator without integrated mapping; Boston Scientific’s Farapulse, emphasizing waveform optimization; and Johnson & Johnson’s Varipulse, focused on variable energy delivery. Medtronic’s Affera offers mapping but requires separate ablation tools.
Kardium’s edge lies in its 122-electrode array for real-time, high-resolution insights during ablation, potentially reducing redo rates. Market share battles will hinge on clinical data, with PULSAR’s 78% success rate comparing favorably to competitors’ pivotal trials (e.g., 66-75% freedom from arrhythmia).
Emerging players like Affera (acquired by Medtronic) and smaller startups are innovating in hybrid energy systems, but Kardium’s single-catheter approach minimizes inventory costs for hospitals.
Future Prospects
Looking ahead, expanded indications for persistent AFib could double addressable markets, with ongoing trials exploring posterior wall isolation and beyond-PVI strategies. Integration with AI-driven mapping could further enhance outcomes, predicting optimal ablation sites based on patient-specific electroanatomy.
For U.S. providers, the Globe System aligns with value-based care models, emphasizing reduced hospitalizations and improved long-term efficacy. As AFib prevalence climbs with aging populations—projected to affect 12 million Americans by 2030—technologies like this promise scalable solutions.
Disclaimer: This news report is provided for informational purposes only. It does not constitute medical, financial, or investment advice. Readers should consult professionals for specific guidance.